Why did 23andMe get sued? Unpacking the Lawsuits and Data Privacy Concerns

Why did 23andMe get sued? Unpacking the Lawsuits and Data Privacy Concerns

In recent years, the popular genetic testing company 23andMe has found itself at the center of several high-profile lawsuits. These legal battles, often complex and with significant implications for both the company and its millions of customers, stem from a variety of issues, primarily revolving around data privacy, security breaches, and alleged misrepresentations about the company's practices. For the average American consumer who has sent their saliva sample to 23andMe in hopes of uncovering their ancestry or understanding their health predispositions, understanding these lawsuits is crucial for making informed decisions about their personal genetic information.

The Genesis of Legal Troubles: Data Security and a Massive Breach

One of the most significant reasons 23andMe faced lawsuits was a substantial data breach that came to light in late 2026. This breach, which affected a large number of customers, involved unauthorized access to user data. The perpetrators reportedly exploited a vulnerability related to credential stuffing attacks, where stolen usernames and passwords from other websites were used to gain access to 23andMe accounts.

What data was compromised? The compromised data included sensitive information such as usernames, display names, profile information, and, most alarmingly, DNA Relatives lists. For many, this list of genetic relatives is a core feature of the 23andMe service, connecting them with individuals who share their DNA. The exposure of these lists raised serious concerns about the privacy of not just the individuals directly affected but also their extended network of genetic relatives who might not have even been direct 23andMe customers.

What were the consequences? Following the announcement of the breach, multiple class-action lawsuits were filed against 23andMe. These lawsuits generally alleged that the company:

• Failed to adequately protect customer data, violating its own privacy policies and data security promises.
• Did not implement sufficient security measures to prevent such a breach from occurring.
• Was negligent in its handling of sensitive genetic information.

These lawsuits sought damages for the harm caused by the breach, including the potential for identity theft, misuse of personal information, and emotional distress.

Beyond the Breach: Other Legal Challenges

While the data breach was a major catalyst for recent lawsuits, 23andMe has faced other legal scrutiny in the past. These have included allegations related to:

Misleading Health Reports and Claims

In the past, 23andMe has also been the subject of lawsuits and regulatory actions concerning the accuracy and marketing of its health reports. Specifically:

• FDA Scrutiny: The U.S. Food and Drug Administration (FDA) has previously issued warning letters to 23andMe, citing concerns about the company's direct-to-consumer genetic testing for health-related information without proper authorization. The FDA has strict regulations for medical devices and diagnostic tests, and 23andMe's early offerings were seen as operating in a gray area.
• Allegations of Misrepresentation: Some lawsuits have alleged that 23andMe made misleading claims about the scientific validity and predictive power of its health reports. Customers may have believed that the reports offered definitive diagnoses or medical advice, when in reality, they provided genetic predispositions that required further medical consultation.

Privacy Policy and Data Sharing

Another area of contention has been 23andMe's privacy policy and how it handles customer data. While the company states that it does not sell personal genetic information, there have been concerns and legal challenges regarding:

• Third-Party Access: Lawsuits have questioned the extent to which 23andMe shares anonymized or aggregated data with third parties for research purposes or even for potential commercial partnerships. While companies often argue this is for scientific advancement, users may not fully understand or consent to these broader data-sharing practices.
• Changes to Privacy Policies: Like many tech companies, 23andMe has updated its privacy policies over time. Lawsuits have sometimes argued that these changes were not adequately communicated to users, or that they allowed for more expansive data usage than users initially agreed to.

What Does This Mean for Consumers?

The lawsuits against 23andMe highlight a broader societal debate about the ownership and security of personal genetic data. As more Americans embrace direct-to-consumer genetic testing, understanding the risks and the legal landscape is paramount.

Key takeaways for consumers include:

• Read the Fine Print: Always thoroughly read and understand a company's terms of service and privacy policy before submitting personal information, especially sensitive genetic data.
• Be Aware of Data Sharing: Understand how your data might be used, even if anonymized or aggregated, for research or other purposes.
• Security Measures: While companies are responsible for data security, consumers should also practice good online hygiene, such as using strong, unique passwords and enabling two-factor authentication where available.
• Consult Healthcare Professionals: Genetic information from services like 23andMe should be viewed as a tool for further discussion with healthcare providers, not as a definitive diagnosis or medical advice.

The legal challenges faced by 23andMe serve as a stark reminder of the delicate balance between the benefits of genetic information and the paramount importance of protecting individual privacy and data security in the digital age.

Frequently Asked Questions (FAQ)

How did 23andMe get sued after the data breach?

Following the late 2026 data breach, where unauthorized actors accessed customer accounts and sensitive information like DNA Relatives lists, multiple class-action lawsuits were filed against 23andMe. These lawsuits generally alleged that the company failed to implement adequate security measures to protect user data, thereby violating its own promises and potentially exposing customers to harm.

Why did 23andMe face scrutiny from the FDA?

23andMe faced scrutiny from the U.S. Food and Drug Administration (FDA) in the past because some of its genetic testing services, particularly those related to health predispositions, were offered directly to consumers without the necessary FDA authorization. The FDA has regulations for medical devices and diagnostic tests, and 23andMe's early health reports were considered to be operating in a regulatory gray area.

What were some of the concerns about 23andMe's privacy policy?

Concerns about 23andMe's privacy policy have revolved around the company's practices for sharing customer data. Lawsuits and public debate have questioned the extent to which 23andMe shares anonymized or aggregated genetic data with third parties for research or potential commercial partnerships. Additionally, changes to privacy policies over time have sometimes led to legal challenges if users felt they weren't adequately informed or that data usage expanded beyond their initial consent.